Key result
A review of 20 papers identified molecular biomarkers, including troponins, NT-proBNP, hFABP, and lactate, as potentially useful for the diagnosis of blunt cardiac injury.
Why the study?
Blunt cardiac injury carries high morbidity and mortality without a widely accepted gold-standard diagnostic test, and molecular biomarkers remain debated and far from clinical application.
Do molecular biomarkers such as troponins, NT-proBNP, hFABP, and lactate improve the diagnosis of blunt cardiac injury?
Do molecular biomarkers such as troponins, NT-proBNP, hFABP, and lactate improve the diagnosis of blunt cardiac injury?
Molecular biomarkers such as troponins, NT-proBNP, hFABP, and lactate show potential for improving the diagnosis of blunt cardiac injury, though they are not yet widely applied in clinical practice.
Answers are grounded in this paper and cite their sources.
Biomarker candidates for blunt cardiac injury remain exploratory; leaves open prospective validation before any diagnostic application.
INTRODUCTION: Blunt cardiac injury (BCI), associated with high morbidity and mortality, involves multiple injuries. With no widely accepted gold standard diagnostic test and molecular biomarkers still in debate and far from application in clinical practice, exploring specific molecular biomarkers of BCI is of great significance. The clarification of molecular biomarkers can improve the diagnosis of BCI, leading to more precise care for victims in various situations. AREAS COVERED: Using the search term 'Biomarker AND Blunt cardiac injury,' we carefully reviewed related papers from June 2004 to June 2024 in PubMed and CNKI. After reviewing, we included 20 papers, summarizing the biomarkers reported in previous studies, and then reviewed molecular biomarkers such as troponins, Nterminal proBtype natriuretic peptide (NT proBNP), hearttype fatty acid binding protein (hFABP), and lactate for BCI diagnosis. Finally, valuable views on future research directions for diagnostic biomarkers of BCI were presented. EXPERT OPINION: Several advanced technologies have been introduced into clinical medicine, which have ultimately changed the research on cardiac diseases in recent years. Some biomarkers have been identified and utilized for BCI diagnosis. Herein, we summarize the latest relevant information as a reference for clinical practice and future studies.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2024) conducted a review in Blunt cardiac injury. Molecular biomarkers (troponins, NT-proBNP, hFABP, lactate) was evaluated on Diagnosis of blunt cardiac injury. A review of 20 papers identified molecular biomarkers, including troponins, NT-proBNP, hFABP, and lactate, as potentially useful for the diagnosis of blunt cardiac injury.
Synapse has enriched 10 related papers. Consider them for comparative context: